Abbott Laboratories announced that its FreeStyle Libre 3 Plus sensor has secured broad public funding across all Canadian provinces, significantly expanding access to the advanced glucose monitoring technology.
- The comprehensive coverage includes federal and employer-sponsored plans, ensuring widespread availability for people with diabetes in Canada.
- Despite the positive market expansion news, Abbott's stock (ABT) is currently trading down 1.01% at $126.50.